Yahoo Web Search

Search results

1. www.linkedin.com › in › dhymanmdDavid Hyman - Eli Lilly and Company | LinkedIn

   www.linkedin.com › in › dhymanmd

   Liked by David Hyman Liked by David Hyman Loxo Oncology, Inc. Congratulations to our Senior VP, Development Strategy Nisha Nanda, for being named to the "2017 Fiercest Women in Life Sciences"…

   • Connections: 500+
   • Followers: 1.9K

   • Works For: Eli Lilly and Company
   • Location: Stamford, Connecticut

2. scholar.google.com › citations‪David M Hyman‬ - ‪Google Scholar‬

   scholar.google.com › citations

   • Cached

   David M Hyman. Loxo Oncology, Eli Lilly. Verified email at loxooncology.com - Homepage. Oncology Precision Medicine Cancer Genomics Developmental Therapeutics Early Drug Development.

3. People also ask

   Who is David Hyman?

   • David Hyman, MD, Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) and global principal investigator of the NAVIGATE trial testing larotrectinib, shared the landmark data from three multisite clinical trials in a press conference at the meeting.

   Results Indicate That Larotrectinib Is Effective as the First Novel

   www.mskcc.org/news-releases/results-indicate-larotrectinib-effective-first-novel-targeted-therapy-show-consistent-response-across-multiple-tumor-types-adult-and-pediatric-patients

   See all results for this question

   What is the focus of Loxo Oncology at Lilly?

   • Areas of focus for Loxo Oncology at Lilly currently include registration of selpercatinib (a selective RET inhibitor), and clinical development of LOXO-305 (a selective, non-covalent BTK inhibitor), LY3499446 (a selective, covalent KRAS G12C inhibitor), and LY3484356 (a selective estrogen receptor degrader).

   Lilly Announces New Leadership and Strategy in Oncology

   investor.lilly.com/news-releases/news-release-details/lilly-announces-new-leadership-and-strategy-oncology-research

   See all results for this question

   Can Loxo-195 be used as a sequential therapy?

   • The unprecedented speed of entry of a next-generation TRK inhibitor in the clinic should also allow LOXO-195 to be tested and developed in predominantly the same patient population as larotrectinib, as a sequential therapy.

   Results Indicate That Larotrectinib Is Effective as the First Novel

   www.mskcc.org/news-releases/results-indicate-larotrectinib-effective-first-novel-targeted-therapy-show-consistent-response-across-multiple-tumor-types-adult-and-pediatric-patients

   See all results for this question

4. investor.lilly.com › news-releases › news-releaseLilly Announces New Leadership and Strategy in Oncology ...

   investor.lilly.com › news-releases › news-release

   • Cached

   Dec 5, 2019 · "The Loxo Oncology acquisition has brought talented people and new approaches to Lilly, and we are excited by what we can achieve by incorporating their discovery and development philosophy at a much larger scale. With the addition of Dr. Hyman, we are further strengthening our leadership team in oncology," said Skovronsky.

5. www.fiercebiotech.com › biotech › lilly-rejigsLilly rejigs cancer R&D—and puts Loxo team in charge

   www.fiercebiotech.com › biotech › lilly-rejigs

   • Cached

   Dec 5, 2019 · By Amirah Al Idrus Dec 5, 2019 10:45am. A cancer R&D rejig comes four months after Lilly’s cancer research chief, Levi Garraway, M.D., Ph.D., departed the Big Pharma to become Roche's chief ...

6. www.mskcc.org › news-releases › results-indicateResults Indicate That Larotrectinib Is Effective as the First ...

   www.mskcc.org › news-releases › results-indicate

   • Cached

   Jun 3, 2017 · Dr. David Hyman, MD Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American ...

7. Images

   • 
   • 
   • 
   • 

   View all

8. www.bloomberg.com › profile › personDavid Hyman, Loxo Oncology Inc: Profile and Biography

   www.bloomberg.com › profile › person

   • Cached

   David Hyman is Chief Medical Officer at Loxo Oncology Inc. See David Hyman's compensation, career history, education, & memberships.

9. theorg.com › org › eli-lillyDavid Hyman - Chief Medical Officer, Loxo Oncology at Eli ...

   theorg.com › org › eli-lilly

   • Cached

   Show contact. David Hyman, currently Chief Medical Officer at Eli Lilly and Company and Loxo@Lilly, has a significant background in the medical field. Prior to their current roles, David served as an Associate Member and Chief of Early Drug Development at Memorial Sloan Kettering Cancer Center. Additionally, David was an Associate Professor of ...